A pharmaceutical company is formulating a new medication that prevents painful gout attacks. However, the lead researchers are also mindful of its impacts to the human liver, which can be indicated by...

Extracted text: A pharmaceutical company is formulating a new medication that prevents painful gout attacks. However, the lead researchers are also mindful of its impacts to the human liver, which can be indicated by monitoring levels of alanine aminotransferase (or ALT, in U/L units). If the ALT levels exceed an average of 55 U/L, there is an indication of the drug having damaging effects to the liver. Let us assume that ALT levels are normally distributed with standard deviation of 15.7 U/L. To determine the consequence of this new drug, they randomly selected 162 adult men with gout and monitored levels of alanine aminotransferase (or ALT, in U/L units) after taking the new medicine for 6 months. From the sample, it is found that the average ALT level is 59 U/L. It is suspected levels are significantly increased. Conduct a test of significance with a=0.05. What is your conclusion in the context of the problem? There is an indication of the new medication having damaging effects to the human liver as indicated by the significantly decreased ALT levels. There is an indication of the new medication having damaging effects to the human liver as indicated by the significantly increased ALT levels. There is no indication of the new medication having damaging effects to the human liver as indicated by a lack of sufficient evidence to support significantly different ALT levels. At 95% level of significance, there is no indication of the new medication having damaging effects to the human liver. There is no indication of the new medication having damaging effects to the human liver as indicated by a lack of sufficient evidence to support significantly increased ALT levels.